Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This study is a local, prospective, non-interventional, non-controlled, multicenter,
observational study (regulatory postmarketing surveillance). Each physician will enroll
patients who have received at least 1 dose of Yervoy, and each patient will be followed for
up to 12 months. All patients will be evaluated for safety and effectiveness during Yervoy
use (4 doses) and for 12 months from the first dose of Yervoy to confirm the safety profile
of Yervoy under routine, daily practice